4D Molecular Therapeutics to Participate in Upcoming Investor Conferences

General Motors, Genuine Parts, Steel Dynamics And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

U.S. stock futures were mixed as GM shares fell 7.3% despite an earnings beat; FreightCar America, 4D Molecular and others also declined premarket.

Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Lowers Price Target to $25

Chardan Capital analyst Gautam Chukka maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and lowers the price target from $26 to $25.

B of A Securities Maintains Buy on 4D Molecular Therapeutics, Raises Price Target to $33

B of A Securities analyst Tazeen Ahmad maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and raises the price target from $29 to $33.

8-K filing — 4D Molecular Therapeutics, Inc. (FDMT)

Filed: 2026-09-28 AccNo: 0001193125-26-403424 Size: 150 KB Item 8.01: Other Events

4D Molecular Therapeutics Announces First Patients Enrolled In Phase 3 Trial Of 4D-150 In Diabetic Macular Edema; 2-Year Data Show 61% Fewer Injections

Scholastic Posts Downbeat Q1 Results, Joins Legacy Education, Zscaler And Other Big Stocks Moving Lower In Friday’s Pre-Market Session

U.S. stock futures rose, but Scholastic plunged 9.9% after missing Q1 loss and sales estimates; several other stocks also fell premarket.